{"product_id":"when-one-illness-overshadows-another-chronic-disease-patients-may-miss-out-on-treatment-for-other-conditions","title":"When One Illness Overshadows Another: Chronic Disease Patients May Miss Out on Treatment for Other Conditions","description":"\u003cp\u003eThis large Canadian study examined whether patients with a chronic disease are less likely to receive treatment for other, unrelated medical problems. Researchers analyzed prescription records for 1,344,145 Ontario residents aged 65 and older and found that patients with diabetes, emphysema, or psychotic syndromes were significantly less likely to receive treatment for unrelated conditions — even though all patients had free access to prescription medications. The pattern appeared consistently across all three chronic diseases and held up even after adjusting for age and sex. This suggests that one illness can unintentionally \"overshadow\" other important health needs.\u003c\/p\u003e\n\n\u003ch1\u003eWhen One Illness Overshadows Another: Chronic Disease Patients May Miss Out on Treatment for Other Conditions\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-finding-1\"\u003eKey Finding 1: Diabetes and Estrogen Replacement Therapy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-finding-2\"\u003eKey Finding 2: Emphysema and Cholesterol-Lowering Medications\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-finding-3\"\u003eKey Finding 3: Psychotic Syndromes and Arthritis Treatment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#additional-analyses\"\u003eWhen Patients Were NOT Overlooked\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat These Results Mean for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Clinicians\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn 1,344,145 Ontario seniors with free drug coverage, chronic disease patients were less likely to get unrelated treatments.\u003c\/li\u003e\n\u003cli\u003eDiabetes was tied to 60% lower odds of estrogen therapy; emphysema to 31% lower odds of cholesterol-lowering drugs.\u003c\/li\u003e\n\u003cli\u003ePsychotic syndromes were associated with 41% lower odds of arthritis medication use.\u003c\/li\u003e\n\u003cli\u003eBreast cancer patients got glaucoma treatment normally, and hypothyroid patients got antibiotics normally.\u003c\/li\u003e\n\u003cli\u003eUndertreatment was not due to cost or access, since all patients had free medication coverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003ePatients can have several illnesses at the same time. Yet some of those diseases may be neglected when one problem consumes all the attention. \"Nature has no mercy,\" the authors write — one disease provides no immunity against others. In a large population, the coincidental occurrence of two unrelated diseases must happen often.\u003c\/p\u003e\n\n\u003cp\u003eBut human reasoning has blind spots. One common error is the \"gambler's fallacy\" — the misconception that bad luck tends to be followed by good luck. In medicine, this might create a belief that unusual coincidences are extremely unlikely in any individual patient. This belief can be reinforced by \u003cstrong\u003eOccam's razor\u003c\/strong\u003e, a scientific principle that urges investigators to use the simplest explanation to explain all observed facts.\u003c\/p\u003e\n\n\u003cp\u003eResearch in nonmedical situations shows that reasoning can be inconsistent even when two problems are clearly separate. For example, a $200 cost seems less expensive when placed next to a $20,000 expenditure than when considered alone. This decreased cost-consciousness helps explain why consumers make imprudent choices, such as purchasing an overpriced radio when buying a reasonably priced automobile.\u003c\/p\u003e\n\n\u003cp\u003eMore generally, secondary problems may receive too little attention when they occur alongside a larger problem. Medical training encourages clinicians to consider a broad \u003cstrong\u003edifferential diagnosis\u003c\/strong\u003e (the full range of possible conditions) in each patient. One classic teaching dictum states: \"Even psychiatric patients can have surgical diseases.\" However, the authors hypothesized that fundamental mistakes in reasoning are not eliminated by formal medical training. Their specific question: Are patients less likely to receive treatment for selected unrelated disorders if they have a chronic medical disease than if they do not?\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe study took place in Ontario, Canada, in 1995. Ontario was chosen because it is Canada's largest province, home to about one third of the country's population. That year, Ontario had a population of 11,008,400, with 25,624 licensed physicians, 6,201 licensed dentists, and $3.5 billion in Ontario Drug Benefit expenditures.\u003c\/p\u003e\n\n\u003cp\u003eAll residents aged 65 or older were included — a total of \u003cstrong\u003e1,344,145 people\u003c\/strong\u003e (56 percent were women, with a mean age of 74). These patients received prescription medications free of charge through the \u003cstrong\u003eOntario Drug Benefit program\u003c\/strong\u003e, meaning financial barriers to treatment did not exist. This universal coverage made Canada an ideal setting to test whether chronic disease leads to undertreatment of unrelated conditions.\u003c\/p\u003e\n\n\u003ch3\u003eHow Patients with Chronic Diseases Were Identified\u003c\/h3\u003e\n\n\u003cp\u003eResearchers selected three chronic systemic medical diseases that are complicated to manage and identifiable through medication prescriptions:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiabetes mellitus\u003c\/strong\u003e (diabetes) — identified by any prescription for insulin\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePulmonary emphysema\u003c\/strong\u003e (a chronic lung disease that damages the air sacs) — identified by any prescription for ipratropium bromide (an inhaled medication)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePsychotic syndromes\u003c\/strong\u003e (severe mental health conditions involving hallucinations or delusions) — identified by any prescription for haloperidol (an antipsychotic medication)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese identification methods were imperfect. Some patients with emphysema never receive ipratropium bromide (false negatives), and some without emphysema do receive it (false positives). Both types of errors tend to weaken statistical comparisons and can bias the analysis toward finding no differences — making any observed differences more meaningful.\u003c\/p\u003e\n\n\u003ch3\u003eChoosing the Unrelated Treatments\u003c\/h3\u003e\n\n\u003cp\u003eFor each chronic disease, the researchers selected one unrelated treatment that met four criteria:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eThe treatment was not directly related to the cause or management of the chronic disease.\u003c\/li\u003e\n  \u003cli\u003eThe treatment was not indirectly related through a shared underlying risk factor.\u003c\/li\u003e\n  \u003cli\u003eThe treatment was relatively straightforward but possibly less important than the chronic disease therapy.\u003c\/li\u003e\n  \u003cli\u003eThe treatment was not trivial and would require follow-up.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe three pairings chosen in advance were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEstrogen-replacement therapy\u003c\/strong\u003e (hormone treatment for menopause symptoms) for patients with diabetes\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLipid-lowering medications\u003c\/strong\u003e (cholesterol-lowering drugs, including statins) for patients with emphysema\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedical arthritis treatment\u003c\/strong\u003e (medications for joint inflammation) for patients with psychotic syndromes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eComprehensive Medication Lists\u003c\/h3\u003e\n\n\u003cp\u003eThe researchers used an exhaustive approach to identify these treatments. \u003cstrong\u003eEstrogen-replacement therapy\u003c\/strong\u003e could be oral or transdermal (skin patch) and included conjugated estrogens, esterified estrogens, 17-beta-estradiol, and combinations containing ethinyl estradiol.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLipid-lowering medications\u003c\/strong\u003e included cholestyramine, colestipol, clofibrate, bezafibrate, fenofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, and fluvastatin.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMedical arthritis treatment\u003c\/strong\u003e included auranofin, aurothioglucose, gold sodium thiomalate, diclofenac, etodolac, fenoprofen, floctafenine, flurbiprofen, hydroxychloroquine, ibuprofen, indomethacin, ketoprofen, ketorolac, naproxen, piroxicam, sulindac, tenoxicam, tiaprofenic acid, and tolmetin. This category included both \u003cstrong\u003eNSAIDs\u003c\/strong\u003e (nonsteroidal anti-inflammatory drugs, such as ibuprofen) and \u003cstrong\u003eDMARDs\u003c\/strong\u003e (disease-modifying antirheumatic drugs, such as gold compounds and hydroxychloroquine).\u003c\/p\u003e\n\n\u003ch3\u003eSupplementary Analyses and Statistical Methods\u003c\/h3\u003e\n\n\u003cp\u003eTwo additional analyses tested situations where researchers expected \u003cem\u003eno\u003c\/em\u003e difference. First, they identified patients with a history of breast cancer (by prescriptions for tamoxifen) and checked whether they received glaucoma treatment (eye drops including betaxolol, carbachol, dipivefrin, echothiophate, levobunolol, pilocarpine, and timolol). Second, they identified patients with hypothyroidism (underactive thyroid, by prescriptions for thyroxine) and checked whether they received antibiotic treatment for acute infections. Both pairings were selected in advance, and the comparisons were prespecified.\u003c\/p\u003e\n\n\u003cp\u003eAll comparisons were two-tailed and expressed as \u003cstrong\u003eodds ratios\u003c\/strong\u003e (a measure of how much less or more likely treatment was). The researchers used the chi-square test to compare proportions and logistic regression (a statistical method) to adjust for imbalances in age and sex. The estrogen analysis excluded all men. To check reliability, all 1995 comparisons were replicated using separate 1995 data from 1990, coded and analyzed by the same methods.\u003c\/p\u003e\n\n\u003cp\u003ePatient confidentiality was protected with unique encrypted numbers that allowed data linkage while preserving anonymity. Medications were coded by Drug Identification Number from claims filed electronically by pharmacies.\u003c\/p\u003e\n\n\u003ch2 id=\"key-finding-1\"\u003eKey Finding 1: Diabetes and Estrogen Replacement Therapy\u003c\/h2\u003e\n\n\u003cp\u003eThe study included \u003cstrong\u003e30,669 patients with diabetes mellitus\u003c\/strong\u003e (55 percent women, mean age 74). These patients were significantly less likely to receive estrogen-replacement therapy than other patients in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe numbers tell the story clearly: only \u003cstrong\u003e2.4 percent\u003c\/strong\u003e of women with diabetes received estrogen replacement, compared with \u003cstrong\u003e5.9 percent\u003c\/strong\u003e of women without diabetes (P\u0026lt;0.001). In absolute terms, that is about 24 of every 1,000 women with diabetes receiving treatment, versus 59 of every 1,000 women without diabetes.\u003c\/p\u003e\n\n\u003cp\u003eIn statistical terms, diabetes was associated with a \u003cstrong\u003e60 percent reduction in the odds\u003c\/strong\u003e of receiving estrogen treatment (odds ratio, 0.40; 95 percent confidence interval, 0.37 to 0.43). A \u003cstrong\u003econfidence interval\u003c\/strong\u003e is a range that likely contains the true value; because this range stays far below 1.0, the finding is robust. The 60 percent reduction persisted after adjusting for age and after restricting the analysis to women (99.5 percent of those who received estrogen prescriptions were women). The reduction appeared for both oral and transdermal preparations, and analysis of 1990 data showed a similar 61 percent reduction (95 percent confidence interval, 55 to 66 percent).\u003c\/p\u003e\n\n\u003ch2 id=\"key-finding-2\"\u003eKey Finding 2: Emphysema and Cholesterol-Lowering Medications\u003c\/h2\u003e\n\n\u003cp\u003eOverall, \u003cstrong\u003e56,779 patients had pulmonary emphysema\u003c\/strong\u003e (46 percent women, mean age 76). These patients were less likely to receive lipid-lowering medications than other patients.\u003c\/p\u003e\n\n\u003cp\u003eOnly \u003cstrong\u003e6.3 percent\u003c\/strong\u003e of emphysema patients received cholesterol-lowering drugs, versus \u003cstrong\u003e8.7 percent\u003c\/strong\u003e of other patients (P\u0026lt;0.001). In absolute terms, that is about 63 of every 1,000 emphysema patients, compared with 87 of every 1,000 patients without emphysema.\u003c\/p\u003e\n\n\u003cp\u003eEmphysema was associated with a \u003cstrong\u003e31 percent reduction in the odds\u003c\/strong\u003e of receiving lipid-lowering treatment (odds ratio, 0.69; 95 percent confidence interval, 0.67 to 0.72; P\u0026lt;0.001). The reduction persisted after adjusting for both age and sex (a 23 percent reduction), was found for both \u003cstrong\u003estatin\u003c\/strong\u003e and \u003cstrong\u003enon-statin\u003c\/strong\u003e agents (32 percent and 21 percent reductions, respectively), and was also present in 1990 (35 percent reduction).\u003c\/p\u003e\n\n\u003ch2 id=\"key-finding-3\"\u003eKey Finding 3: Psychotic Syndromes and Arthritis Treatment\u003c\/h2\u003e\n\n\u003cp\u003eSimilarly, \u003cstrong\u003e17,336 patients had psychotic syndromes\u003c\/strong\u003e (64 percent women, mean age 80). These patients were significantly less likely to receive medical treatment for arthritis.\u003c\/p\u003e\n\n\u003cp\u003eJust \u003cstrong\u003e18 percent\u003c\/strong\u003e of patients with psychotic syndromes received arthritis medication, compared with \u003cstrong\u003e27 percent\u003c\/strong\u003e of other patients (P\u0026lt;0.001). In absolute terms, that is 18 of every 100 patients versus 27 of every 100 patients — a substantial gap for a painful, treatable condition.\u003c\/p\u003e\n\n\u003cp\u003ePsychotic syndromes were associated with a \u003cstrong\u003e41 percent reduction in the odds\u003c\/strong\u003e of arthritis treatment (odds ratio, 0.59; 95 percent confidence interval, 0.57 to 0.62; P\u0026lt;0.001). The reduction persisted after adjusting for age and sex (38 percent), appeared for both NSAIDs (41 percent reduction) and DMARDs (55 percent reduction), and was present in the 1990 data as well (40 percent reduction).\u003c\/p\u003e\n\n\u003ch2 id=\"additional-analyses\"\u003eWhen Patients Were NOT Overlooked\u003c\/h2\u003e\n\n\u003cp\u003eThe relative neglect of unrelated disorders was not a universal finding. Two situations showed that doctors \u003cem\u003edid\u003c\/em\u003e treat separate conditions normally.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003e11,094 patients with breast cancer\u003c\/strong\u003e were just as likely to receive glaucoma treatment as other patients (5.1 percent versus 4.8 percent, P\u0026gt;0.20 — not a statistically significant difference). The \u003cstrong\u003e140,460 patients with hypothyroidism\u003c\/strong\u003e were slightly \u003cem\u003emore\u003c\/em\u003e likely to receive treatment for acute infections than other patients (56 percent versus 54 percent, P\u0026lt;0.001). Apparently, these unrelated diseases were distinct enough that patients received treatment regardless of their chronic condition.\u003c\/p\u003e\n\n\u003ch3\u003eCross-Comparisons Reveal the Full Picture\u003c\/h3\u003e\n\n\u003cp\u003eThe table below shows all nine cross-comparisons from the study. Each comparison used data from all 1,344,145 patients. For example, the first entry compares 30,669 women with diabetes against the rest of the population.\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"6\" cellspacing=\"0\"\u003e\n  \u003ccaption\u003e\n\u003cstrong\u003eTable 2 Data: Percentage Receiving Each Unrelated Treatment, by Chronic Disease Status\u003c\/strong\u003e (P\u0026lt;0.001 for all nine comparisons)\u003c\/caption\u003e\n  \u003ctr\u003e\n    \u003cth\u003eChronic Disease\u003c\/th\u003e\n    \u003cth\u003eEstrogen Therapy — Disease Present\u003c\/th\u003e\n    \u003cth\u003eEstrogen Therapy — Disease Absent\u003c\/th\u003e\n    \u003cth\u003eLipid-Lowering — Disease Present\u003c\/th\u003e\n    \u003cth\u003eLipid-Lowering — Disease Absent\u003c\/th\u003e\n    \u003cth\u003eArthritis Treatment — Disease Present\u003c\/th\u003e\n    \u003cth\u003eArthritis Treatment — Disease Absent\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDiabetes mellitus\u003c\/td\u003e\n    \u003ctd\u003e2.4%\u003c\/td\u003e\n    \u003ctd\u003e5.9%\u003c\/td\u003e\n    \u003ctd\u003e11.4%\u003c\/td\u003e\n    \u003ctd\u003e8.5%\u003c\/td\u003e\n    \u003ctd\u003e25%\u003c\/td\u003e\n    \u003ctd\u003e27%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePulmonary emphysema\u003c\/td\u003e\n    \u003ctd\u003e4.2%\u003c\/td\u003e\n    \u003ctd\u003e5.9%\u003c\/td\u003e\n    \u003ctd\u003e6.3%\u003c\/td\u003e\n    \u003ctd\u003e8.7%\u003c\/td\u003e\n    \u003ctd\u003e25%\u003c\/td\u003e\n    \u003ctd\u003e27%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePsychotic syndromes\u003c\/td\u003e\n    \u003ctd\u003e1.8%\u003c\/td\u003e\n    \u003ctd\u003e5.9%\u003c\/td\u003e\n    \u003ctd\u003e2.1%\u003c\/td\u003e\n    \u003ctd\u003e8.7%\u003c\/td\u003e\n    \u003ctd\u003e18%\u003c\/td\u003e\n    \u003ctd\u003e27%\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eDifferent pairings yielded different results — and one positive association. Patients with diabetes were actually \u003cem\u003emore\u003c\/em\u003e likely to receive lipid-lowering therapy than others (11.4 percent versus 8.5 percent). This makes medical sense: hyperglycemia (high blood sugar) is associated with dyslipidemia (abnormal blood fats). However, the observed 38 percent relative increase was smaller than the roughly 100 percent increase expected based on some epidemiology studies. In other words, even the \"correct\" association was smaller than it should have been.\u003c\/p\u003e\n\n\u003cp\u003ePatients with emphysema had a 29 percent relative reduction in estrogen treatment, even though smoking is a known risk factor for emphysema, heart disease, and osteoporosis (thinning bones) — meaning this group might have deserved \u003cem\u003emore\u003c\/em\u003e estrogen, not less. Emphysema patients had only a 7 percent relative reduction in arthritis treatment, possibly because lung symptoms feel distinct from joint symptoms. Patients with psychotic syndromes, however, were consistently unlikely to receive \u003cem\u003eany\u003c\/em\u003e of the three unrelated treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat These Results Mean for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe most important finding is the \u003cstrong\u003einverse correlation\u003c\/strong\u003e (an opposite relationship) between having a chronic disease and the likelihood of receiving treatment for an unrelated disorder. In no case did the chronic disease justify withholding an effective medical treatment.\u003c\/p\u003e\n\n\u003cp\u003eThe results are compatible with the theory that one disease provides \"protection\" against other diseases — but that theory is unlikely to be correct, given medical pathophysiology and shared underlying risk factors. Instead, the findings suggest a shortfall in health care: unrelated disorders are relatively neglected in patients with chronic medical diseases.\u003c\/p\u003e\n\n\u003cp\u003eThe chosen unrelated treatments had important implications for each chronic disease:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiabetes:\u003c\/strong\u003e Patients with diabetes are at increased risk for atherosclerosis (hardening of the arteries) and may be particularly likely to benefit from estrogen-replacement therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEmphysema:\u003c\/strong\u003e The reserve capacity of patients with emphysema is seriously compromised. They may be unable to tolerate even a small cardiovascular event (such as a heart attack or stroke), making cholesterol treatment especially valuable.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePsychotic syndromes:\u003c\/strong\u003e These patients are often sensitive to discomfort, and joint pain might theoretically worsen their mental status. Treating arthritis could protect their mental health as well as their physical comfort.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn all three examples, inadvertent undertreatment may have real consequences. These examples resemble other reported cases of mistakes in caring for patients who have more than one illness.\u003c\/p\u003e\n\n\u003cp\u003eThe study found, however, that undertreatment cannot be blamed on cost or paperwork. The results cannot be attributed to a general tendency toward prescribing multiple medications for the elderly, since that would work against finding any negative associations. Nor can they be blamed on barriers to medical access, insurance status, or ability to pay — all patients had free drug coverage. Fraud (such as multiple people sharing one insurance card) also does not explain the findings.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eThe authors acknowledge several important limitations, of which three merit emphasis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, this was not a randomized trial.\u003c\/strong\u003e It is impossible to randomly assign patients to have or not have a chronic disease. Subtle \u003cstrong\u003econfounding\u003c\/strong\u003e (hidden factors that distort results) could have contributed to — and possibly justified — the observed differences. However, imbalances related to age, sex, insurance status or carrier, ability to pay, or random chance would not explain the findings.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, optimal rates of these treatments are controversial.\u003c\/strong\u003e In theory, the findings could be explained by overtreatment of patients who \u003cem\u003edo not\u003c\/em\u003e have chronic diseases. If true, that would represent a different — and potentially more common — failure in medical decision making.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, the underlying mechanism remains unknown.\u003c\/strong\u003e Future research must determine whether the second disease is simply \u003cem\u003enot detected\u003c\/em\u003e in the presence of the first, or whether it is \u003cem\u003edetected but not treated\u003c\/em\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe observed results might arise from several sources. Patients with chronic diseases may feel exhausted and reluctant to accept multiple interventions. Clinicians are often busy and may strive to keep care simple — particularly when they do not have extra time for patients with more complicated conditions. A chronic disease, especially chronic psychosis, may limit communication between patient and doctor. Even universal insurance coverage could contribute if the implicit goal of equity is achieved by \"doing something for all but a lot for none.\"\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Clinicians\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to note that unrelated treatments are \u003cem\u003enot always\u003c\/em\u003e indicated for patients with chronic diseases. The authors offer several cautions:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eChronic diseases are sometimes associated with reduced life expectancy, making long-term preventive therapy unrewarding.\u003c\/li\u003e\n  \u003cli\u003eAdding supplementary medications increases the risk of unwanted \u003cstrong\u003edrug interactions\u003c\/strong\u003e and potential adverse events.\u003c\/li\u003e\n  \u003cli\u003ePrescribing additional medications might alter a patient's compliance with essential medications and indirectly cause harm.\u003c\/li\u003e\n  \u003cli\u003eTime constraints, communication problems, patient preferences, and the priorities of specialists can make it difficult to address more than one problem effectively in a single visit.\u003c\/li\u003e\n  \u003cli\u003eIt is often sensible to postpone minor treatments until major problems are resolved.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDespite these cautions, the findings highlight a vital role for clinicians who can provide a comprehensive approach to patient care. Contrary to popular opinion, such comprehensive care was not fully evident in the mid-1990s even under the Canadian system of universal health insurance.\u003c\/p\u003e\n\n\u003cp\u003eFor \u003cstrong\u003epatients\u003c\/strong\u003e, this study offers actionable advice:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eKeep an updated list of all your medical conditions and bring it to every appointment.\u003c\/li\u003e\n  \u003cli\u003eMention new symptoms even if they seem unrelated to your main chronic condition.\u003c\/li\u003e\n  \u003cli\u003eAsk your doctor directly about preventive treatments — such as cholesterol or bone health medications — if you have a chronic disease.\u003c\/li\u003e\n  \u003cli\u003eDo not assume a new ache or symptom is \"just part\" of your existing illness. Ask for an evaluation.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003ePrimary care physicians may be well suited to this coordinating role, since the diversity of their practices makes them responsive to diverse issues. Yet specific training may be required to overcome fundamental pitfalls in reasoning. Alternatively, a health care system might develop programs that ensure comprehensive care and avoid focusing solely on well-defined single problems, while minimizing failures of individual judgment. Although chronic diseases are frequent and unrelated disorders are common, the authors conclude, the inevitable coincidences are relatively neglected in clinical practice. Patients and doctors alike should remember: one disease does not protect against another, and treating the whole patient means looking beyond the most obvious diagnosis.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat did this Canadian study find about treating unrelated conditions in chronic disease patients?\u003c\/h3\u003e\n\u003cp\u003eIn a study of 1,344,145 Ontario seniors with free drug coverage, those with diabetes, emphysema, or psychotic syndromes were significantly less likely to receive treatment for certain unrelated conditions. For example, women with diabetes had lower estrogen therapy use, and emphysema patients had lower cholesterol medication use. This suggests one illness may overshadow other health needs.\u003c\/p\u003e\n\u003ch3\u003eWhy were Ontario seniors chosen for this study?\u003c\/h3\u003e\n\u003cp\u003eOntario was Canada's largest province and provided free prescription medications to all residents aged 65 or older through the Ontario Drug Benefit program. This eliminated financial barriers, allowing researchers to test whether chronic disease leads to undertreatment of unrelated conditions without cost being a factor. The study included all 1,344,145 eligible seniors.\u003c\/p\u003e\n\u003ch3\u003eWhich specific chronic diseases and unrelated treatments were studied?\u003c\/h3\u003e\n\u003cp\u003eResearchers paired three chronic diseases with unrelated treatments: diabetes with estrogen-replacement therapy, emphysema with lipid-lowering (cholesterol) medications, and psychotic syndromes with arthritis medications. These pairings were chosen in advance because the treatments were unrelated to the chronic disease and not trivial.\u003c\/p\u003e\n\u003ch3\u003eWere there any situations where doctors did treat unrelated conditions normally?\u003c\/h3\u003e\n\u003cp\u003eYes. Patients with breast cancer were just as likely to receive glaucoma treatment as others, and patients with hypothyroidism were slightly more likely to receive antibiotics for acute infections. These comparisons were included as controls and suggest that undertreatment was not universal but specific to certain chronic disease and treatment pairings.\u003c\/p\u003e\n\u003ch3\u003eWhat should patients with chronic diseases do based on this study?\u003c\/h3\u003e\n\u003cp\u003ePatients should keep an updated list of all medical conditions and bring it to every appointment, mention new symptoms even if seemingly unrelated, and ask directly about preventive treatments. The study advises not assuming a new symptom is just part of an existing illness and requesting evaluation. Discussing all health concerns with your doctor is important.\u003c\/p\u003e\n\u003ch3\u003eI have a chronic disease like diabetes, emphysema, or a psychotic syndrome — could a second opinion help make sure I am not missing treatment for an unrelated condition?\u003c\/h3\u003e\n\u003cp\u003eIn a large Ontario study of older adults with free prescription drug coverage, patients with diabetes, emphysema, or psychotic syndromes were significantly less likely than others to receive treatment for unrelated conditions. For example, diabetes was associated with 60% lower odds of estrogen therapy in women, and psychotic syndromes were associated with 41% lower odds of arthritis treatment. Chronic disease can unintentionally overshadow other health needs. Patients and clinicians should remember that one disease does not protect against another. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e The Treatment of Unrelated Disorders in Patients with Chronic Medical Diseases\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAuthors:\u003c\/strong\u003e Donald A. Redelmeier, M.D., Siew H. Tan, M.A., and Gillian L. Booth, M.D.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJournal:\u003c\/strong\u003e The New England Journal of Medicine, 1998; Volume 338, pages 1516-1520 (May 21, 1998 issue)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInstitution:\u003c\/strong\u003e Department of Medicine, University of Toronto; Clinical Epidemiology and Health Care Research Program, Sunnybrook Health Science Centre; and the Institute for Clinical Evaluative Sciences in Ontario, Toronto, Canada\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from your healthcare provider.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576718737564,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/ja\/products\/when-one-illness-overshadows-another-chronic-disease-patients-may-miss-out-on-treatment-for-other-conditions","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}